Type 2 diabetes patients on pioglitazone treatment had a fivefold increased risk of developing macular edema compared with nonusers, a Japanese study found. The risk of macular edema was more than 11 times higher in patients on both insulin and pioglitazone therapy compared with those on neither medication, research showed. The results were presented at the European Association for the Study of Diabetes meeting.

Related Summaries